The business unit numares HEALTH develops innovative in vitro diagnostic (IVD) tests for a variety of indications. The basis of the test developments is the human metabolism that mirrors pathophysiological changes (use of metabolomics methodology). The IVD tests are non-invasive tests on the basis of human body fluids such as blood or urine that can make medical diagnostics and prevention of diseases possible at an early stage and enable therapies to be monitored. One of the things numares HEALTH is currently working on is the development of a CE-marked laboratory test for better assessing the risk of cardiovascular diseases. The company's goal is to integrate its medical products into laboratory diagnostics and put them into clinical routine.
"In keeping with the VDGH ‘mission statement' to" improve preventive health measures and curative medical care", we feel optimally supported by the association in the "development and supply of innovative products with great benefits for patients and society" says Dr. Volker Pfahlert, CEO of numares HEALTH, commenting on the company’s membership in the trade association. "The VDGH provides us with the latest information on all relevant political, economic and regulatory decisions, as well as assistance and professional advice. The best possible foundation for numares HEALTH to market innovative in vitro diagnostics economically and successfully based on mutual cooperation and interaction between the association and its members."
Media contact
numares AG
Dipl.-Biol. Christiane Proll, MBA
Tel.: +49 941 2809 49-14
E-Mail: christiane.proll(at)numares.com
IRA WÜLFING KOMMUNIKATION GmbH
Dr. Reinhard Saller
Tel.: +49 89 2000 30-38
E-Mail: reinhard.saller(at)wuelfing-kommunikation.de